| Oct 24 |
Aprea Therapeutics presents preliminary results on APR-1051
|
| Oct 23 |
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
|
| Oct 23 |
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations
|
| Oct 23 |
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
|
| Oct 14 |
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
|
| Sep 25 |
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
|
| Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
| Sep 12 |
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
|
| Aug 28 |
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
|
| Aug 12 |
Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M
|
